pfizer glp-1 drug Danuglipron: An Oral GLP-1R Agonist Competing with Peptide Injectables for Diabetes and Obesity ADA '26: Lilly's dominance, Pfizer's

Overall, the EASD-ADA consensus provides a dynamic framework that supports a multifaceted, patient-centric approach to type 2 diabetes care, aiming to reduce complications, improve quality of life, and promote long-term health outcomes

Drug safety isnt just about innovation

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

Jardiance (empagliflozin) 38% CV death reduction vs Mounjaro (tirzepatide) 21% weight loss (EMPA-REG vs SURPASS)

Learn the most common and serious GLP-1 side effects, including nausea, constipation, pancreatitis risk, and when to seek medical attention.

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence